MicroVision, Inc.
27.4.2022 22:21:08 CEST | ACCESS Newswire | Press release
REDMOND, WA / ACCESSWIRE / April 27, 2022 / MicroVision, Inc. (NASDAQ:MVIS), a leader in MEMS-based solid-state automotive lidar and ADAS solutions, today announced its first quarter 2022 results.
"We made significant progress in the first quarter of 2022. We track tested our integrated Long Range Lidar sensor and perception software, demonstrating promising ground-truth data of our high-fidelity/low-latency solution at speeds of over 60 mph," said Sumit Sharma, MicroVision's Chief Executive Officer. "We continue to receive positive feedback and interest from automotive OEMs and Tier 1 suppliers for our best-in-class product with cost advantages."
"We began our testing in the U.S. and expect to conduct several more rounds of tests of our high-speed Highway Pilot system both in the U.S. and Germany during the second quarter as we work to deliver on our 2022 objectives," continued Sharma.
Key Financial Highlights for Q1 2022
- Revenue for the first quarter of 2022 was $0.4 million, compared to $0.5 million for the first quarter of 2021.
- Net loss for the first quarter of 2022 was $13.2 million, or $0.08 per share, which includes $3.7 million of non-cash, share-based compensation expense, compared to a net loss of $6.2 million, or $0.04 per share, which includes $1.6 million of non-cash, share-based compensation expense, for the first quarter of 2021.
- Adjusted EBITDA for the first quarter of 2022 was negative $9.0 million, compared to negative $4.3 million in the first quarter of 2021.
- Cash used in operations for the first quarter of 2022 was $10.9 million, compared to cash used in operations for the first quarter in 2021 of $4.5 million.
- The Company ended the first quarter of 2022 with $103.3 million in cash and cash equivalents including investment securities, compared to $115.4 million at the end of December 31, 2021.
Conference Call and Webcast: Q1 2022 Results
MicroVision will host a conference call and webcast, consisting of prepared remarks by management, a slide presentation, and a question-and-answer session at 2:00 PM PT/5:00 PM ET on Wednesday, April 27, 2022 to discuss the financial results and provide a business update. Analysts and investors may pose questions for management during the live webcast on April 27, 2022.
The live webcast and slide presentation can be accessed on the Company's Investor Relations website under the Events tab at https://ir.microvision.com/events. The webcast will be archived on the website for future viewing.
About MicroVision
MicroVision is a pioneering company in MEMS based laser beam scanning technology that integrates MEMS, lasers, optics, hardware, algorithms and machine learning software into its proprietary technology to address existing and emerging markets. The Company's integrated approach uses its proprietary technology today to develop automotive lidar sensors and provide solutions for advanced driver-assisted systems (ADAS), leveraging its experience building augmented reality micro-display engines, interactive display modules and consumer lidar modules.
For more information, visit the Company's website at www.microvision.com, on Facebook at www.facebook.com/microvisionincor follow MicroVision on Twitter at @MicroVision.
MicroVision is a trademark of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.
Non-GAAP information
To supplement MicroVision's condensed financial statements presented in accordance with GAAP, the Company presents investors with the non-GAAP financial measure "adjusted EBITDA." Adjusted EBITDA consists of GAAP net income (loss) excluding the impact of the following: interest income and interest expense; income tax expense; depreciation and amortization; and share-based compensation.
MicroVision believes that the presentation of adjusted EBITDA provides important supplemental information to management and investors regarding financial and business trends, provides consistency and comparability with MicroVision's past financial reports, and facilitates comparisons with other companies in the Company's industry, many of which use similar non-GAAP financial measures to supplement their GAAP results. Internally, management uses this non-GAAP measure when evaluating operating performance because the exclusion of the items described above provides an additional useful measure of the Company's operating results and facilitates comparisons of the Company's core operating performance against prior periods and its business objectives. Externally, the Company believes that adjusted EBITDA is useful to investors in their assessment of MicroVision's operating performance and the valuation of the Company.
Adjusted EBITDA is not calculated in accordance with GAAP, and should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Non-GAAP financial measures have limitations in that they do not reflect all of the costs associated with the operations of MicroVision's business as determined in accordance with GAAP. The Company expects to continue to incur expenses similar to the non-GAAP adjustments described above, and exclusion of these items from its non-GAAP financial measure should not be construed as an inference that these costs are unusual or infrequent. The Company compensates for limitations of the measure by prominently disclosing GAAP net income (loss), which the Company believes is the most directly comparable GAAP measure, and providing investors with a reconciliation from GAAP net income (loss) to adjusted EBITDA.
MicroVision has included a reconciliation of GAAP net income (loss) to adjusted EBITDA for the relevant periods.
Forward-Looking Statements
Certain statements contained in this release, including the Company's plans regarding product demonstration and product capabilities are forward-looking statements that involve a number of risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those projected in such forward-looking statements include the risk its ability to operate with limited cash or to raise additional capital when needed; market acceptance of its technologies and products or for products incorporating its technologies; the failure of its commercial partners to perform as expected under its agreements, including from the impact of COVID-19 (coronavirus); its financial and technical resources relative to those of its competitors; its ability to keep up with rapid technological change; government regulation of its technologies; its ability to enforce its intellectual property rights and protect its proprietary technologies; the ability to obtain customers and develop partnership opportunities; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market its products; potential product liability claims; its ability to maintain its listing on The Nasdaq Stock Market, and other risk factors identified from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the SEC. These factors are not intended to represent a complete list of the general or specific factors that may affect the Company. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this release may affect the Company to a greater extent than indicated. Except as expressly required by federal securities laws, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.
MicroVision, Inc.
Balance Sheet
(In thousands)
(Unaudited)
| March 31, | December 31, | |||||||
| 2022 | 2021 | |||||||
Assets | ||||||||
Current Assets | ||||||||
Cash and cash equivalents | $ | 55,611 | $ | 82,647 | ||||
Investment securities, available-for-sale | 47,651 | 32,720 | ||||||
Inventory | 1,815 | 1,780 | ||||||
Other current assets | 1,865 | 2,283 | ||||||
Total current assets | 106,942 | 119,430 | ||||||
Property and equipment, net | 3,248 | 3,026 | ||||||
Operating lease right-of-use asset | 5,368 | 5,577 | ||||||
Restricted cash | 1,092 | 1,092 | ||||||
Intangible assets, net | 105 | 115 | ||||||
Other assets | 1,014 | 985 | ||||||
Total assets | $ | 117,769 | $ | 130,225 | ||||
Liabilities and Shareholders' Equity | ||||||||
Current Liabilities | ||||||||
Accounts payable | $ | 1,919 | $ | 3,584 | ||||
Accrued liabilities | 1,288 | 1,170 | ||||||
Contract liabilities | 4,915 | 5,265 | ||||||
Other current liabilities | 474 | 1,181 | ||||||
Current portion of long-term debt | 98 | 392 | ||||||
Current portion of operating lease liability | 686 | 849 | ||||||
Current portion of finance lease obligations | 24 | 21 | ||||||
Total current liabilities | 9,404 | 12,462 | ||||||
Operating lease liability, net of current portion | 4,882 | 4,983 | ||||||
Finance lease obligations, net of current portion | 15 | 26 | ||||||
Total liabilities | 14,301 | 17,471 | ||||||
Commitments and contingencies | ||||||||
Shareholders' Equity | ||||||||
Common stock at par value | 165 | 164 | ||||||
Additional paid-in capital | 746,028 | 742,042 | ||||||
Accumulated other comprehensive loss | (124 | ) | (19 | ) | ||||
Accumulated deficit | (642,601 | ) | (629,433 | ) | ||||
Total shareholders' equity | 103,468 | 112,754 | ||||||
Total liabilities and shareholders' equity | $ | 117,769 | $ | 130,225 | ||||
MicroVision, Inc.
Statement of Operations
(In thousands, except earnings per share data)
(Unaudited)
| Three months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
Product revenue | $ | - | $ | - | ||||
License and royalty revenue | 350 | 479 | ||||||
Total revenue | 350 | 479 | ||||||
Cost of product revenue | 4 | (5 | ) | |||||
Total cost of revenue | 4 | (5 | ) | |||||
Gross margin | 346 | 484 | ||||||
Research and development expense | 7,593 | 4,462 | ||||||
Sales, marketing, general and administrative expense | 5,877 | 2,247 | ||||||
Total operating expenses | 13,470 | 6,709 | ||||||
Loss from operations | (13,124 | ) | (6,225 | ) | ||||
Other expense, net | (44 | ) | (6 | ) | ||||
Net loss | $ | (13,168 | ) | $ | (6,231 | ) | ||
Net loss per share - basic and diluted | $ | (0.08 | ) | $ | (0.04 | ) | ||
Weighted-average shares outstanding - basic and diluted | 164,563 | 155,454 | ||||||
MicroVision, Inc.
Reconciliation of GAAP Net Loss to Non-GAAP Measure
(In thousands, except earnings per share data)
(Unaudited)
| Three months ended March 31, | ||||||||
| 2022 | 2021 | |||||||
GAAP net loss | $ | (13,168 | ) | $ | (6,231 | ) | ||
Add Interest (net) | (31 | ) | 5 | |||||
Add Income taxes | - | - | ||||||
Add Depreciation & amorization | 483 | 299 | ||||||
Add Share-based compensation expense | 3,734 | 1,638 | ||||||
Adjusted EBITDA | $ | (8,982 | ) | $ | (4,289 | ) | ||
Investor Relations Contact
Jeff Christensen and Matt Kreps
Darrow Associates Investor Relations
MVIS@darrowir.com
SOURCE: MicroVision, Inc.
View source version on accesswire.com:
https://www.accesswire.com/699143/MicroVision-Announces-First-Quarter-2022-Results
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI Mojave First UAS To Complete Battlefield Short Field Ops16.9.2026 19:30:00 CEST | Press release
Short Takeoff and Landing Aircraft Validates Austere Field Capabilities SAN DIEGO, CA / ACCESS Newswire / September 16, 2026 / General Atomics Aeronautical Systems (GA-ASI) and Hanwha Aerospace have completed the first-ever flight operations from a simulated battlefield by a medium altitude, long endurance uncrewed aircraft. The partners proved that the Mojave Short Takeoff and Landing aircraft, or Mojave STOL, could land at a tank and artillery live-fire range during simulated combat conditions and then take off again to continue the mission. "This demonstration showcased Mojave's ability to perform tactical missions that are representative of real battlefield requirements and challenges," said GA-ASI CEO Linden Blue. "Whether the user needs contested and austere battlefield operations, ISR, weapons delivery, Air-Launched Effects deployment, troop resupply, counter-UAS, or missions requiring short and unimproved roads for takeoff, our aircraft answer the bell." "This demonstration mar
Freedom Holding Corp. Named General Partner of the Salesforce FIDE World Championship Match 202616.9.2026 16:13:00 CEST | Press release
Partnership builds on Freedom's long-term support for international chess as Geneva prepares to host the historic Gukesh - Sindarov title match NEW YORK CITY, NY / ACCESS Newswire / September 16, 2026 / Freedom Holding Corp. (NASDAQ:FRHC) will serve as General Partner of the Salesforce FIDE World Championship Match 2026, continuing a long-standing partnership with the International Chess Federation (FIDE) spanning elite competition, education and chess development. Freedom's involvement in the 2026 World Championship follows several years of cooperation with FIDE. The company was General Partner of the 2023 World Championship Match in Astana and title sponsor of the 2024 FIDE World Rapid & Blitz Championships in New York, one of FIDE's flagship global events. It has also supported international competitions and initiatives focused on expanding access to chess, developing young talent and strengthening the wider chess ecosystem. Earlier this year, Freedom and FIDE further expanded their
Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics16.9.2026 13:00:00 CEST | Press release
Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune disease, transplantation and oncology Union of two companies brings together Santersus' NucleoCapture® technology, designed to physically remove NETs from circulation, with Xenetic's DNase technology, designed to enzymatically degrade NETs in tissue Joint pipeline includes four first-in-class programs, including pivotal-stage programs in sepsis and systemic lupus erythematosus (SLE), both of which have received FDA Breakthrough Device Designation Companies to host Business Update Conference Call and Webcast Today, Wednesday, September 16th at 8:30 AM ET FRAMINGHAM, MA / ACCESS Newswire / September 16, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company advancing its Deoxyribonuclease ("DNase") technology, and Santersus AG ("Santersus"), a privately held
DataTracks Completes First Live GloBE Filing Cycle, Delivering Close to 500 Pillar Two Filings Across 10+ Jurisdictions16.9.2026 11:15:00 CEST | Press release
HMRC-authorised provider completes close to 500 Pillar Two filings, including more than 150 GIRs, for 160+ clients across 10+ jurisdictions WEYBRIDGE, GB / ACCESS Newswire / September 16, 2026 / DataTracks, recognised by HMRC as an authorised software provider supporting UK Pillar Two submissions, has completed its first live BEPS Pillar Two filing cycle, delivering close to 500 filings, including more than 150 GIRs, across 10+ jurisdictions for more than 160 clients. The milestone caps two decades of work in regulatory reporting. The cycle spanned GloBE Information Returns (GIR), domestic top-up tax returns under local QDMTT (Qualified Domestic Minimum Top-up Tax) regimes, UK Overseas Return Notifications (ORNs), and other jurisdiction-specific returns and notifications. Several jurisdictions in this cycle, including the Netherlands and Luxembourg, require similar notifications confirming where the GIR was filed centrally, under their own local terms. DataTracks filed each return dire
Hydrosat Unveils Osiris Constellation, The Future of Thermal Intelligence16.9.2026 08:00:00 CEST | Press release
Next-generation satellite constellation will combine high-resolution thermal imaging with broad-area coverage and daily revisit to support governments, businesses, and researchers worldwide. PARIS, FR / ACCESS Newswire / September 16, 2026 / Hydrosat, the leading provider of thermal infrared satellite data and AI-powered analytics, today announced Osiris, its next-generation Earth observation constellation designed to deliver wide-area, high resolution intelligence for water and food security, critical infrastructure, and national security missions. At the core of each Osiris satellite is Hydrosat's next-generation thermal infrared payload, developed to collect high-resolution thermal data across exceptionally wide areas. Operating across three longwave infrared bands, the payload will capture imagery at 25-meter native resolution over 160-kilometer to 340-kilometer swath widths, addressing one of Earth observation's biggest challenges between spatial detail and collection scale. This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
